[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN111246881A - Pd-1抗体用于治疗肿瘤的用途 - Google Patents

Pd-1抗体用于治疗肿瘤的用途 Download PDF

Info

Publication number
CN111246881A
CN111246881A CN201880059067.9A CN201880059067A CN111246881A CN 111246881 A CN111246881 A CN 111246881A CN 201880059067 A CN201880059067 A CN 201880059067A CN 111246881 A CN111246881 A CN 111246881A
Authority
CN
China
Prior art keywords
antibody
antigen
binding fragment
ctla
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880059067.9A
Other languages
English (en)
Other versions
CN111246881B (zh
Inventor
张力
方文峰
邹建军
杨清
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SUN YAT-SEN UNIVERSITY CANCER HOSPITAL
Jiangsu Hengrui Medicine Co Ltd
Original Assignee
SUN YAT-SEN UNIVERSITY CANCER HOSPITAL
Jiangsu Hengrui Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SUN YAT-SEN UNIVERSITY CANCER HOSPITAL, Jiangsu Hengrui Medicine Co Ltd filed Critical SUN YAT-SEN UNIVERSITY CANCER HOSPITAL
Publication of CN111246881A publication Critical patent/CN111246881A/zh
Application granted granted Critical
Publication of CN111246881B publication Critical patent/CN111246881B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

提供了PD‑1抗体用于治疗肿瘤的用途。具体而言，提供了抗PD‑1抗体或其抗原结合片段在制备治疗曾接受抗CTLA‑4抗体或其抗原结合片段治疗的肿瘤患者的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (22)

  1. PCT国内申请，权利要求书已公开。
CN201880059067.9A 2017-12-14 2018-12-13 Pd-1抗体用于治疗肿瘤的用途 Active CN111246881B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201711340839 2017-12-14
CN201711340839X 2017-12-14
CN2018110549530 2018-09-10
CN201811054953 2018-09-10
PCT/CN2018/120819 WO2019114785A1 (zh) 2017-12-14 2018-12-13 Pd-1抗体用于治疗肿瘤的用途

Publications (2)

Publication Number Publication Date
CN111246881A true CN111246881A (zh) 2020-06-05
CN111246881B CN111246881B (zh) 2023-03-10

Family

ID=66818946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880059067.9A Active CN111246881B (zh) 2017-12-14 2018-12-13 Pd-1抗体用于治疗肿瘤的用途

Country Status (3)

Country Link
CN (1) CN111246881B (zh)
TW (1) TW201927821A (zh)
WO (1) WO2019114785A1 (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023030532A1 (zh) * 2021-09-06 2023-03-09 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合
CN116549633A (zh) * 2022-12-28 2023-08-08 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗鼻咽癌患者的药物中的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118576599A (zh) * 2020-10-23 2024-09-03 和记黄埔医药（上海）有限公司 一种药物组合产品在制备用于治疗非小细胞肺癌的药物中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085847A1 (zh) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用
WO2017054646A1 (zh) * 2015-09-28 2017-04-06 江苏恒瑞医药股份有限公司 一种抗pd-1抗体制剂及其在医药上的应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015085847A1 (zh) * 2013-12-12 2015-06-18 上海恒瑞医药有限公司 Pd-1抗体、其抗原结合片段及其医药用途
WO2017054646A1 (zh) * 2015-09-28 2017-04-06 江苏恒瑞医药股份有限公司 一种抗pd-1抗体制剂及其在医药上的应用
CN106110322A (zh) * 2016-07-29 2016-11-16 安徽瀚海博兴生物技术有限公司 一种药物组合物及其在制备治疗癌症药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHIUN HSU ET AL: "Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study", 《《JOURNAL OF CLINICAL ONCOLOGY》》, vol. 35, no. 36, 24 August 2017 (2017-08-24), pages 4050 - 4056 *
MARGARET K.CALLAHAN ET AL: "CTLA-4 and PD-1 path way blockade:combinations in the clinic", 《FRONTIERS IN ONCOLOGY》, vol. 4, no. 385, 31 January 2015 (2015-01-31), pages 1 - 6 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023030532A1 (zh) * 2021-09-06 2023-03-09 正大天晴药业集团股份有限公司 用于治疗食管癌的药物组合
CN116549633A (zh) * 2022-12-28 2023-08-08 广州誉衡生物科技有限公司 抗-pd-1抗体及其在制备治疗鼻咽癌患者的药物中的用途

Also Published As

Publication number Publication date
CN111246881B (zh) 2023-03-10
TW201927821A (zh) 2019-07-16
WO2019114785A1 (zh) 2019-06-20

Similar Documents

Publication Publication Date Title
US11498972B2 (en) Anti-OX40 antibody and use thereof
JP2020090509A (ja) 非小細胞肺がんを治療するための抗ｂ７−ｈ１および抗ｃｔｌａ−４抗体
CN108473578A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
WO2018223923A1 (zh) Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途
AU2010297258A1 (en) Dosage regimen for administering an EpCAMxCD3 bispecific antibody
CN112512580B (zh) Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
CN111246881A (zh) Pd-1抗体用于治疗肿瘤的用途
CN112007162B (zh) Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN109663130B (zh) Pd-1抗体和mek抑制剂联合在制备治疗肿瘤的药物中的用途
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
TW202133886A (zh) 用於增強免疫及腫瘤治療之方法
CN109793892B (zh) 一种抗pd-1抗体在制备治疗食管癌的药物中的用途
CN110859959A (zh) 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途
WO2021057764A1 (zh) Pd-1抗体联合紫杉类化合物在制备治疗三阴性乳腺癌的药物中的用途
TWI814752B (zh) 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途
CN110812485A (zh) 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
CN113491769A (zh) 药物联合
TW202207982A (zh) 可活化之抗ctla-4抗體之給藥及投與
CN110507820A (zh) 一种抗pd-1抗体联合放射疗法在制备治疗肿瘤患者的药物中的用途
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
WO2023227115A1 (en) A method of treating solid tumor
TW202241512A (zh) 結合ctla-4的抗體及其用途
WO2024183623A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
WO2024183622A1 (zh) 一种抗her2抗体在制备治疗癌症的药物中的用途
JP2023538683A (ja) 鼻咽頭癌の治療における抗ｐｄ－１抗体の使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant